Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumours or Lymphomas
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Alisertib (Primary) ; Esomeprazole; Rifampicin
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda Oncology
- 30 Aug 2017 Results investigating the effect of gastric acid reducing agents and strong inducers/inhibitors of CYP3A4 on the pharmacokinetics of alisertib published in the Investigational New Drugs
- 18 Aug 2017 Results published in the Investigational New Drugs.
- 29 Sep 2016 Status changed from active, no longer recruiting to completed.